美國商業資訊

2024-10-09 09:59

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC).
With bladder cancer now the ninth most diagnosed cancer around the world 1, securing the global supply of this innovative bladder-sparing treatment is vital.

SAINT-PREX, Switzerland--()--Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s capabilities and capacity to meet the current and expected growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC).

Adstiladrin® (nadofaragene firadenovec-vncg) is approved in the U.S. for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumours.

“In January this year, we announced full commercial availability of Adstiladrin® in the U.S. We have now embarked on a broad programme of clinical research to enlarge the body of evidence for Adstiladrin® and plan for regulatory submissions in other global markets. Today’s announcement marks an important milestone in ensuring stable and sustainable global supply of Adstiladrin® to meet the anticipated growth in demand,” said Bipin Dalmia, Global Head, Uro-Oncology and Urology Franchise, Ferring Pharmaceuticals.

Armin Metzger, Executive Vice President and Chief Technical Operations Officer, Ferring Pharmaceuticals added, “The continued investment and expansion of our gene therapy manufacturing infrastructure reflects Ferring’s strong commitment to deliver end-to-end solutions for even the most highly complex manufacturing challenges as part of our mission to fulfil the unmet clinical needs for people with bladder cancer.”

According to the International Agency for Research on Cancer, bladder cancer is now the ninth most diagnosed cancer worldwide, previously ranked tenth.1 This rising global incidence underscores the necessity to expand the supply of innovative treatments for this disease.

In addition to this European investment in drug substance, Ferring has further strengthened and diversified its nadofaragene firadenovec-vncg supply chain and is also nearing completion of a new manufacturing facility for drug product at Ferring’s U.S. campus in Parsippany, New Jersey. The bolstering of Ferring’s gene therapy manufacturing capabilities and footprint reinforces its commitment to ensuring the future supply of this therapy for patients.

Located in Kuopio, Finland, the new European manufacturing site features a cutting-edge manufacturing suite, fully integrated with modern technology to produce adenovirus vector-based gene therapy drug substance in large quantities. The 25,000 square metre facility features renewable energy solutions such as waste heat recovery with heat pumps and solar energy, complementing Ferring’s commitment to protect the environment by reducing its negative impact on the planet.

About Adstiladrin® (nadofaragene firadenovec-vncg)
Adstiladrin® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.2 It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder’s cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body’s own natural defences against the cancer.3

Adstiladrin® (nadofaragene firadenovec-vncg) has been studied in a clinical trial programme that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment (full inclusion criteria published on clinicaltrials.gov: NCT02773849).3

About non-muscle invasive bladder cancer (NMIBC)
NMIBC is a form of bladder cancer in which the tumour is not invading into or beyond the muscularis propia.4 Bladder cancer is the 9th most common cancer worldwide, with 614,298 new cases reported in 2022.5 75% of bladder cancers present as NMIBC.6 In patients with high-risk NMIBC, intravesical BCG remains the first-line standard of care.7 Current treatment options for BCG-unresponsive patients are very limited outside of radical cystectomy (partial or complete removal of the bladder).7 In a patient choice experiment to determine preferred treatment options for NMIBC, 89% of patients never selected radical cystectomy as their preferred option; patients were willing to accept a 43.8% increased risk of progression and a 66.1% increase in the risk of serious side effects to increase the time to radical cystectomy from 1 year to 6 years.8

About gene therapy and the manufacturing process
Gene therapies aim to treat, prevent, or cure diseases by modifying or manipulating gene expression or altering the biological properties of living cells. 9 The concept involves techniques like adding new copies of a gene or replacing faulty genes with healthy ones.10 Over the decades, gene therapies have been applied to inherited genetic diseases, cancers, and other disorders. Viral vectors, bacterial vectors, plasmid DNA, human gene editing, and patient-derived cellular gene therapies are various forms of gene therapy.9 Viral vectors are particularly significant due to their high transduction efficiency and stable expression, offering potentially curative treatments with fewer applications.11 Successful applications include treatments for bladder cancer, leukaemia, lymphoma, haemophilia, certain neurological disorders, retinal diseases, and metabolic disorders.12-18

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedInInstagramYouTubeFacebook and X(Twitter).

© 2024 Ferring. Ferring and the Ferring Pharmaceuticals logo are trademarks of the Ferring group of companies.

References:

  1. International Agency for Research on Cancer. GLOBOCAN 2022 factsheet. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf [Accessed July 2024].
  2. U.S. FDA. ADSTILADRIN. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin [Accessed July 2024].
  3. ClinicalTrials.gov. ADSTILADRIN in patients with high grade, Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). Gov Identifier: NCT02773849. Available from: https://clinicaltrials.gov/ct2/show/NCT02773849 [Accessed July 2024].
  4. Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020 Jul; 22(2):43-51.
  5. International Agency for Research on Cancer. Cancer Today. Available from: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group_populations=1&key=total [Accessed July 2024].
  6. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 May; 63(2):234-41.
  7. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 Nov 27; 22:107-17.
  8. Collacott H, Krucien N, Heidenreich S, Catto JWF, Ghatnekar O. Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment. Eur Urol Open Sci. 2023 Jan 31;49:92-99.
  9. U.S. FDA. What is gene therapy? Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy [Accessed July 2024].
  10. NIH. Gene Therapy. Available from: https://www.genome.gov/genetics-glossary/Gene-Therapy [Accessed July 2024].
  11. Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020 Feb;22(2):57-69
  12. Munis AM. Gene therapy applications of non-human lentiviral vectors. Viruses. 2020 Sep 29; 12:1106. doi: 10.3390/v12101106.
  13. Miyake H, et al. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia. 2005 Feb; 7(2): 171-9. doi:10.1593/neo.04478.
  14. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor t cells for sustained remissions in leukemia. New England Journal of Medicine. 2014 Oct 16; 371(16), 1507-1517.
  15. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New England Journal of Medicine. 2014 Nov 20; 371(21), 1994-2004.
  16. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Experimental Neurology. 2000 Jul; 164(1), 2-14.
  17. Russell, S., Bennett, J., Wellman, J. A., et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet. 2017 Aug 26; 390(10097), 849-860.
  18. Seker Yilmaz B, Gissen P. Genetic therapy approaches for ornithine transcarbamylase deficiency. Biomedicines. 2023 Aug 8; 11(8):2227. doi: 10.3390/biomedicines11082227.

Contacts

Matthew Worrall
Director of Corporate Communications and Public Affairs, Ferring Pharmaceuticals
Matthew.worrall@ferring.com

Matt Handcock
Senior Account Manager, Syneos Health Communications
Matt.handcock@syneoshealth.com

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞! ► 即睇詳情

人氣文章
最近7天
1
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
2
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
3
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
4
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
5
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
6
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
7
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
8
新股上市 | 布魯可傳延遲上市,港交所:FINI顯示有誤,續按上市時間表進行
9
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
10
騰訊 | 被美列中國軍事企業名單,騰訊稱非軍工供應商願與美方解決誤會(附名單)
1
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
2
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
3
利率波動難測 如何以債券策略爭取「財息兼收」?
4
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
5
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
6
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
7
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
8
高息定存 | 一周高息合集,華僑1個月定存4厘208日3.8厘
9
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
10
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
11
資源有限窒礙中小企轉型? 營商生態圈助你開拓無限商機!
12
2025年環球經濟與輪證投資前瞻
13
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
14
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
15
回顧展望-共渡時艱 | 表列機構對今明年本港經濟增長預測
16
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
17
回顧展望-樓盡六壬 | 甲廈租金明年料跌9%,華潤頻買民生商場
18
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
19
【FOCUS】「無厘頭」減息釀驚嚇,長債失控顯聯儲失信譽
20
中經會 | 中證監:堅決落實「穩住樓市股市」,維護資本市場穩定
21
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
22
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
23
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
24
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
25
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
26
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
27
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
28
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
29
【FOCUS】防資本外逃+擴過境免簽,減國際收支壓力
30
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet 賞你】賞 MOKO x Cheeky Cheeky「厚」有福氣利是封 及「熊 MEOW 」火柴盒造型年曆卡!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老